日本臨牀 80/増刊4 最新関節リウマチ学(第2版)

出版社: 日本臨牀社
発行日: 2022-04-30
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 最新関節リウマチ学(第2版)
電子書籍版: 2022-04-30 (第2版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

24,200 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

24,200 円(税込)

目次

  • 特集 最新関節リウマチ学(第2版)
       ―寛解・治癒を目指した研究と最新治療

    I 総論
     1.関節リウマチの概念
     2.関節リウマチの歴史
     3.関節リウマチの自然経過、生命予後と規定因子
     4.関節の構造と機能

    II 病因と病態
     1.関節リウマチの病因研究とその進歩
     2.関節リウマチの病態研究とその進歩

    III 関節リウマチの検査・診断
     1.関節リウマチの臨床症候・検査・診断:アイロン
     2.臨床症候
     3.検査
     4.診断
     5.類縁疾患、鑑別診断が必要な疾患
     
    IV 関節リウマチの治療
     1.治療総論
     2.治療各論
     3.外科治療
     
    V 関節リウマチの臓器障害と合併症・薬剤副作用対策
     1.呼吸器系障害(間質性肺疾患を含む)
     2.胸膜・心外膜障害
     3.肝、胆、膵、消化管障害(HB/C肝炎、薬剤性を含む)
     4.腎障害(薬剤性を含む)
     5.神経・筋障害(薬剤性を含む)
     6.眼障害
     7.口腔障害―特にドライマウスとその口腔内合併症について―
     8.悪性腫瘍、リンパ増殖性疾患
     9.血管障害(血管炎症候群、過敏性血管炎を含む)
     10.アミロイドーシス
     11.感染症(薬剤性日和見感染症を含む)
     12.造血系、凝固異常(薬剤性を含む)
     13.骨粗鬆症、骨折(薬剤性を含む)

    VI 特論
     1.ドラッグホリデー
     2.関節リウマチ疾患のプレシジョンメディスン
     3.マルチオミックス解析
     4.AIを用いた関節リウマチ医療
     5.iPS細胞を用いた骨・軟骨再生
     6.間葉系幹細胞の制御による関節軟骨の再生
     7.筋、腱、靱帯再生
     8.関節リウマチとCOVID-19、感染、予防

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.5 掲載の参考文献
1) Smolen JS, et al : Rheumatoid arthritis. Nat Rev Dis Primers 4 : 18001, 2018.
2) McInnes IB, Schett G : Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389 : 2328-2337, 2017.
3) Tanaka Y : Rheumatoid arthritis. Inflamm Regen 40 : 20, 2020.
4) Tanaka Y : Rheumatoid arthritis : DMARD de-escalation-let the patient guide you. Nat Rev Rheumatol 13 : 637-638, 2017.
5) Schett G, et al : Why remission is not enough : underlying disease mechanisms in RA that prevent cure. Nat Rev Rheumatol 17 : 135-144, 2021.

I 総論

P.13 掲載の参考文献
1) Entezami P, et al : Historical perspective on the etiology of rheumatoid arthritis. Hand Clin 27 : 1-10, 2011.
2) McInnes IB, Schett G : The pathogenesis of rheumatoid arthritis. N Engl J Med 365 : 2205-2219, 2011.
3) Aletaha D, et al : 2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 : 2569-2581, 2010.
4) O'Dell JR, et al : Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369 : 307-318, 2013.
5) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69 : 964-975, 2010.
6) Felson DT, et al : American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63 : 573-586, 2011.
7) Taylor PC, et al : Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 376 : 652-662, 2017.
P.18 掲載の参考文献
1) Entezami P, et al : Historical perspective on the etiology of rheumatoid arthritis. Hand Clin 27 : 1-10, 2011.
2) リウマチ性疾患の歴史. リウマチ入門 第11版 [日本語版] (原著 : アメリカ関節炎財団編, 日本語版 : 日本リウマチ学会編), p1-9, 萬有製薬, 1999.
3) Benedek TG, et al : A brief history of the rheumatic diseases. Bull Rheum Dis 32 : 59-68, 1982.
4) Storey GO, et al : Chronic arthritis before 1876 : early British cases suggesting rheumatoid arthritis. Ann Rheum Dis 53 : 557-560, 1994.
5) Landre-Beauvais AJ : The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine 68 : 130-143, 2001.
6) Parish LC : An historical approach to the nomenclature of rheumatoid arthritis. Arthritis Rheum 6 : 138-158, 1963.
7) Storey GD : Alfred Baring Garrod (1819-1907). Rheumatology (Oxford) 40 : 1189-1190, 2001.
8) Dequeker J, Rico H : Rheumatoid arthritis-like deformities in an early 16th-century painting of the Flemish-Dutch school. JAMA 268 : 249-251, 1992.
9) Dequeker J : Arthritis in Flemish paintings (1400-1700). Br Med J 1 : 1203-1205, 1977.
10) Rothschild BM, et al : Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 241 : 1498-1501, 1988.
11) Kacki S : Erosive polyarthropathy in a Late Roman skeleton from northern France : A new case of rheumatoid arthritis from the pre-Columbian Old Word? Int J Paleopathol 3 : 59-63, 2013.
12) Kwiecinski J, Rothschild BM : No rheumatoid arthritis in ancient Egypt : a reappraisal. Rheumatol Int 36 : 891-895, 2016.
13) Basic Z, et al : Rich but poor : life in the Roman period with extreme rheumatoid arthritis. Clin Rheumatol 36 : 235-238, 2017.
14) Inoue K, et al : Erosive peripheral polyarthritis in ancient Japanese skeletons : A possible case of rheumatoid arthritis. Int J Osteoarchaeol 9 : 1-7, 1999.
15) 小澤修造 : 運動器疾患. 内科學 [第7版] (入澤達吉監), p531-552, 南山堂書店, 1933.
P.24 掲載の参考文献
1) Masi AT : Articular patterns in the early course of rheumatoid arthritis. Am J Med 75 : 16-26, 1983.
2) Ochi T, et al : Serum C1q levels as a prognostic guide to articular erosions in patients with rheumatoid arthritis. Arthritis Rheum 27 : 883-887, 1984.
3) 西野仁樹 : リウマチ小読本, アークメディア, 2000.
4) Lard LR, et al : Early versus delayed treatment in patients with recent-onset rheumatoid arthritis : comparison of two cohorts who received different treatment strategies. Am J Med 111 : 446-451, 2001.
5) van Nies JA, et al : Evaluating relationships between symptom duration and persistence of rheumatoid arthritis : does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts. Ann Rheum Dis 74 : 806-812, 2015.
6) Becede M, et al : Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum 49 : 211-217, 2019.
7) Wolfe F, et al : The Mortality of Rheumatoid Arthritis. Arthritis Rheum 37 : 481-494, 1994.
8) Gabriel SE, et al : Survival in rheumatoid arthritis : a population-based analysis of trends over 40 years. Arthritis Rheum 48 : 54-58, 2003.
9) Lunt M, et al : No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 62 : 3145-3153, 2010.
10) Listing J, et al : Mortality in rheumatoid arthritis : the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74 : 415-421, 2015.
11) Nakajima A, et al : Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol 39 : 360-367, 2010.
12) Nakajima A, et al : No increased mortality in patients with rheumatoid arthritis treated with biologics : results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23 : 945-952, 2013.
13) Chiu YM, et al : Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis : A Nationwide Cohort Followed Up From 2003 to 2016. Arthritis Rheumatol 73 : 750-758, 2021.
14) Olson AL, et al : Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 183 : 372-378, 2011.
15) Hyldgaard C, et al : A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease : comorbidity and mortality. Ann Rheum Dis 76 : 1700-1706, 2017.
16) Manfredi A, et al : Rheumatoid arthritis related interstitial lung disease. Expert Rev Clin Immunol 17 : 485-497, 2021.
17) Sparks JA, et al : Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease : A Prospective Cohort Study. Arthritis Rheumatol 71 : 1472-1482, 2019.
18) Izuka S, et al : Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease : clinical features and prognosis. Rheumatology (Oxford) 60 : 2348-2354, 2021.
P.31 掲載の参考文献
1) Metabolic, Degenerative and Inflammatory Diseases of Bones and Joints (ed by Jaffe H), Lea & Febiger, Philadelphia, 1972.
2) Schett G : Bone marrow edema. Ann N Y Acad Sci 1154 : 35-40, 2009.
3) Barland P, et al : Electron microscopy of the human synovial membrane. J Cell Biol 14 : 207-220, 1962.
4) Buckley CD, et al : Location, location, location : how the tissue microenvironment affects inflammation in RA. Nat Rev Rheumatol 17 : 195-212, 2021.
5) Davies DV : Anatomy and Physiology of Diarthrodial Joints. Ann Rheum Dis 5 : 29-35, 1945.
6) Knight AD, Levick JR : The density and distribution of capillaries around a synovial cavity. Q J Exp Physiol 68 : 629-644, 1983.
7) Bouta EM, et al : Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis. Nat Rev Rheumatol 14 : 94-106, 2018.
8) Mow VC, et al : Biphasic creep and stress relaxation of articular cartilage in compression? Theory and experiments. J Biomech Eng 102 : 73-84, 1980.
9) Wyke B : The neurology of joints. Ann R Coll Surg Engl 41 : 25-50, 1967.
10) Hebert-Blouin MN, et al : Hilton's law revisited. Clin Anat 27 : 548-555, 2014.
11) Gardner E : The innervation of the hip joint. Anat Rec 101 : 353-371, 1948.

II 病因と病態

P.40 掲載の参考文献
2) Juge PA, et al : MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med 379 : 2209-2219, 2018.
3) Shirai Y, et al : Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese. Ann Rheum Dis 79 : 1305-1309, 2020.
5) Okada Y, et al : Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum Mol Genet 23 : 6916-6926, 2014.
6) Okada Y, et al : Contribution of a Non-classical HLA Gene, HLA-DOA, to the Risk of Rheumatoid Arthritis. Am J Hum Genet 99 : 366-374, 2016.
7) Naito T, et al : A deep learning method for HLA imputation and trans-ethnic MHC fine-mapping of type 1 diabetes. Nat Commun 12 : 1639, 2021.
8) Kallberg H, et al : Smoking is a major preventable risk factor for rheumatoid arthritis : estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70 : 508-511, 2011.
9) Kochi Y, et al : PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Ann Rheum Dis 70 : 512-515, 2011.
10) Wells PM, et al : Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease : a cross-sectional study. Lancet Rheumatol 2 : e418-e427, 2020.
11) Maeda Y, et al : Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis Rheumatol 68 : 2646-2661, 2016.
12) Wegner N, et al : Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase : Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 62 : 2662-2672, 2010.
13) Zhang X, et al : The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 21 : 895-905, 2015.
14) Kishikawa T, et al : Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 79 : 103-111, 2020.
15) Mangalea MR, et al : Individuals at risk for rheumatoid arthritis harbor differential intestinal bacteriophage communities with distinct metabolic potential. Cell Host Microbe 29 : 726-739.e5, 2021.
16) Tomofuji Y, et al : Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease. Ann Rheum Dis 81 : 278-288, 2022.
P.44 掲載の参考文献
1) Frisell T, et al : Familial risks and heritability of rheumatoid arthritis : role of rheumatoid factor/anticitrullinated protein antibody status, number and type of affected relatives, sex, and age. Arthritis Rheum 65 : 2773-2782, 2013.
3) Ha E, et al : Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci. Ann Rheum Dis 80 : 558-565, 2021.
4) Kochi Y, et al : A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42 : 515-519, 2010.
7) van Gaalen FA, et al : Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50 : 2113-2121, 2004.
8) Terao C, et al : Distinct HLA Associations with Rheumatoid Arthritis Subsets Defined by Serological Subphenotype. Am J Hum Genet 105 : 616-624, 2019.
10) Kochi Y, et al : PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Ann Rheum Dis 70 : 512-515, 2011.
11) Ueda H, et al : Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 : 506-511, 2003.
12) Tsuchiya H, et al : Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis. Ann Rheum Dis, 2020. (DOI : 10.1136/annrheumdis-2020-218189)
13) Motegi T, et al : Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling. Ann Rheum Dis 78 : 1062-1069, 2019.
14) Frazer J, et al : Disease variant prediction with deep generative models of evolutionary data. Nature 599 : 91-95, 2021.
15) Canovas R, et al : Genomic risk scores for juvenile idiopathic arthritis and its subtypes. Ann Rheum Dis 79 : 1572-1579, 2020.
P.51 掲載の参考文献
1) Maurano MT, et al : Systematic localization of common disease-associated variation in regulatory DNA. Science 337 : 1190-1195, 2012.
2) Roadmap Epigenomics Consortium ; Kundaje A, et al : Integrative analysis of 111 reference human epigenomes. Nature 518 : 317-330, 2015.
3) ENCODE Project Consortium ; Moore JE, et al : Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature 583 : 699-710, 2020.
4) Lappalainen T, et al : Transcriptome and genome sequencing uncovers functional variation in humans. Nature 501 : 506-511, 2013.
5) GTEx Consortium : The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369 : 1318-1330, 2020.
6) Schmiedel BJ, et al : Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell 175 : 1701-1715.e16, 2018.
7) Ota M, et al : Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell 184 : 3006-3021.e17, 2021.
8) Fairfax BP, et al : Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 343 : 1246949, 2014.
P.56 掲載の参考文献
1) Smolen JS, et al : Rheumatoid arthritis. Nat Rev Dis Primers 4 : 18001, 2018.
2) Carr HL, et al : New Developments in Transcriptomic Analysis of Synovial Tissue. Front Med (Lausanne) 7 : 21, 2020.
3) Buckley CD, et al : Location, location, location : how the tissue microenvironment affects inflammation in RA. Nat Rev Rheumatol 17 : 195-212, 2021.
4) Mizoguchi F, et al : Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun 9 : 789, 2018.
5) Zhang F, et al : Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20 : 928-942, 2019.
6) Croft AP, et al : Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570 : 246-251, 2019.
7) Wei K, et al : Notch signalling drives synovial fibroblast identity and arthritis pathology. Nature 582 : 259-264, 2020.
8) Boutet MA, et al : Novel insights into macrophage diversity in rheumatoid arthritis synovium. Autoimmun Rev 20 : 102758, 2021.
9) Culemann S, et al : Locally renewing resident synovial macrophages provide a protective barrier for the joint. Nature 572 : 670-675, 2019.
10) Kuo D, et al : HBEGF+ macrophages in rheumatoid arthritis induce fibroblast invasiveness. Sci Transl Med 11 : eaau8587, 2019.
11) Alivernini S, et al : Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nat Med 26 : 1295-1306, 2020.
P.61 掲載の参考文献
1) Gregersen PK : Genetics of rheumatoid arthritis : confronting complexity. Arthritis Res 1 : 37-44, 1999.
2) GWAS Catalog (https://www.ebi.ac.uk/gwas/). (2022年2月閲覧)
3) Okamoto H, et al : Molecular aspects of rheumatoid arthritis : role of transcription factors. FEBS J 275 : 4463-4470, 2008.
4) Choi S, et al : Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis. J Clin Invest 127 : 954-969, 2017.
5) Cano-Gamez E, Trynka G : From GWAS to Function : Using Functional Genomics to Identify the Mechanisms Underlying Complex Diseases. Front Genet 11 : 424, 2020.
6) Maurano MT, et al : Systematic localization of common disease-associated variation in regulatory DNA. Science 337 : 1190-1195, 2012.
7) Soskic B, et al : Chromatin activity at GWAS loci identifies T cell states driving complex immune diseases. Nat Genet 51 : 1486-1493, 2019.
8) Ye Y, et al : A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine. Trends Genet 36 : 318-336, 2020.
9) Pelikan RC, et al : Enhancer histone-QTLs are enriched on autoimmune risk haplotypes and influence gene expression within chromatin networks. Nat Commun 9 : 2905, 2018.
11) Ceribelli A, et al : MicroRNAs in rheumatoid arthritis. FEBS Lett 585 : 3667-3674, 2011.
12) Garo LP, et al : MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat Commun 12 : 2419, 2021.
13) Iyer A, et al : MicroRNA-146a : a key regulator of astrocyte-mediated inflammatory response. PLoS One 7 : e44789, 2012.
14) Evangelatos G, et al : MicroRNAs in rheumatoid arthritis : From pathogenesis to clinical impact. Autoimmun Rev 18 : 102391, 2019.
15) Sakaue S, et al : Integration of genetics and miRNA-target gene network identified disease biology implicated in tissue specificity. Nucleic Acids Res 46 : 11898-11909, 2018.
P.67 掲載の参考文献
1) Klareskog L, et al : A new model for an etiology of rheumatoid arthritis : smoking may trigger HLADR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54 : 38-46, 2006.
2) Sugiyama D, et al : Impact of smoking as a risk factor for developing rheumatoid arthritis : a meta-analysis of observational studies. Ann Rheum Dis 69 : 70-81, 2010.
3) Too CL, et al : Occupational exposure to textile dust increases the risk of rheumatoid arthritis : results from a Malaysian population-based case-control study. Ann Rheum Dis 75 : 997-1002, 2016.
4) Hart JE, et al : Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ Health Perspect 117 : 1065-1069, 2009.
5) Chang KH, et al : Air pollution exposure increases the risk of rheumatoid arthritis : A longitudinal and nationwide study. Environ Int 94 : 495-499, 2016.
6) Demmer RT, et al : Periodontal disease, tooth loss and incident rheumatoid arthritis : results from the First National Health and Nutrition Examination Survey and its epidemiological follow-up study. J Clin Periodontol 38 : 998-1006, 2011.
7) Kovacs WJ, Olsen NJ : Sexual dimorphism of RA manifestations : genes, hormones and behavior. Nat Rev Rheumatol 7 : 307-310, 2011.
8) Su FH, et al : Chronic hepatitis C virus infection is associated with the development of rheumatoid arthritis : a nationwide population-based study in Taiwan. PLoS One 9 : e113579, 2014.
9) Zhang X, et al : The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 21 : 895-905, 2015.
10) Chen JY, Ballou SP : The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer. J Rheumatol 42 : 55-59, 2015.
11) Heikkila R, et al : Serum androgen-anabolic hormones and the risk of rheumatoid arthritis. Ann Rheum Dis 57 : 281-285, 1998.
12) Baillargeon J, et al : Hypogonadism and the risk of rheumatic autoimmune disease. Clin Rheumatol 35 : 2983-2987, 2016.
13) Sundstrom B, et al : Interaction between dietary sodium and smoking increases the risk for rheumatoid arthritis : results from a nested case-control study. Rheumatology (Oxford) 54 : 487-493, 2015.
14) Nissen MJ, et al : The effect of alcohol on radiographic progression in rheumatoid arthritis. Arthritis Rheum 62 : 1265-1272, 2010.
15) Di Giuseppe D, et al : Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis : a prospective cohort study of women. Ann Rheum Dis 73 : 1949-1953, 2014.
P.73 掲載の参考文献
2) Pearson CM : Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 91 : 95-101, 1956.
3) DeJoy SQ, et al : Streptococcal cell wall arthritis. Passive transfer of disease with a T cell line and crossreactivity of streptococcal cell wall antigens with Mycobacterium tuberculosis. J Exp Med 170 : 369-382, 1989.
4) Potter M, Wax JS : Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn : reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 127 : 1591-1595, 1981.
5) Kanagawa H, et al : Mycobacterium tuberculosis promotes arthritis development through Toll-like receptor 2. J Bone Miner Metab 33 : 135-141, 2015.
6) Terato K, et al : Collagen-induced arthritis in mice : synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22 : 137-147, 1995.
7) Sakaguchi S : [Cause amd etiological mechanism of rheumatic arthritis using animal models]. Nihon Rinsho Meneki Gakkai Kaishi 23 : 497-498, 2000.
8) Keffer J, et al : Transgenic mice expressing human tumour necrosis factor : a predictive genetic model of arthritis. EMBO J 10 : 4025-4031, 1991.
9) Kontoyiannis D, et al : Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements : implications for joint and gut-associated immunopathologies. Immunity 10 : 387-398, 1999.
13) Niki Y, et al : Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 107 : 1127-1135, 2001.
14) Oike T, et al : IL-6, IL-17 and Stat3 are required for auto-inflammatory syndrome development in mouse. Sci Rep 8 : 15783, 2018.
18) Redlich K, et al : Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110 : 1419-1427, 2002.
19) Takeuchi T, et al : Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study) : a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis 78 : 899-907, 2019.
20) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
21) Nakae S, et al : IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci U S A 100 : 5986-5990, 2003.
22) Kaneko Y, et al : Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment : a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77 : 1720-1729, 2018.
23) Mori T, et al : IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 23 : 701-712, 2011.
24) Oike T, et al : Stat3 as a potential therapeutic target for rheumatoid arthritis. Sci Rep 7 : 10965, 2017.
25) Komatsu N, et al : Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20 : 62-68, 2014.
26) Hasegawa T, et al : Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol 20 : 1631-1643, 2019.
P.79 掲載の参考文献
1) Rothschild BM, et al : Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 241 : 1498-1501, 1988.
2) Garrod A : Discussion on "The Aetiology and Treatment of Osteo-Arthritis and Rheumatoid Arthritis". Proc R Soc Med 17 : 1-4, 1924.
3) Maeda Y, et al : Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis Rheumatol 68 : 2646-2661, 2016.
4) Lawrence JS, Ball J : Genetic studies on rheumatoid arthritis. Ann Rheum Dis 17 : 160-168, 1958.
8) Fassbender HG : Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Coll Relat Res 3 : 141-155, 1983.
9) Tanaka S, et al : Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208 : 30-49, 2005.
10) McInnes IB, Schett G : The Pathogenesis of Rheumatoid Arthritis. N Eng J Med 365 : 2205-2219, 2011.
12) Deane KD, Holers VM : Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention : An Emerging Paradigm Shift. Arthritis Rheumatol 73 : 181-193, 2021.
13) Takahashi D, et al : Microbiota-derived butyrate limits the autoimmune response by promoting the differentiation of follicular regulatory T cells. EBioMedicine 58 : 102913, 2020.
14) Clarke J : Prevotella species associated with RA-risk genes. Nat Rev Rheumatol 16 : 472, 2020.
15) Zhang F, et al : Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20 : 928-942, 2019.
P.83 掲載の参考文献
1) 石田剛, 今村哲夫 : 非腫瘍性骨関節疾患の病理, p21-36, 文光堂, 2003.
2) Orthopaedic Pathology, 5th ed (ed by Bullough PG), p279-302, Mosby Elsevier, St. Loius, 2010.
3) Klein MJ, et al : AFIP Atlas of Nontumor Pathology, Volume 9, Non-Neoplastic Diseases of Bones and Joints, p577-767, American Registry of Pathology, Washington DC, 2011.
4) 小俣康徳, 田中栄 : 関節リウマチ. 骨ペディア-骨疾患・骨代謝キーワード事典 (日本骨代謝学会編), p231-233, 羊土社, 2015.
P.87 掲載の参考文献
1) Malmstrom V, et al : The immunopathogenesis of seropositive rheumatoid arthritis : from triggering to targeting. Nat Rev Immunol 17 : 60-75, 2017.
2) Raj T, et al : Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344 : 519-523, 2014.
3) Shi J, et al : Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 73 : 780-783, 2014.
4) Sokolove J, et al : Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol 66 : 813-821, 2014.
5) Zhang F, et al : Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20 : 928-942, 2019.
6) Loh C, et al : TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes : transcriptomic and epigenomic analysis. Ann Rheum Dis 78 : 1205-1214, 2019.
7) Yokota K, et al : Characterization and Function of Tumor Necrosis Factor and Interleukin-6-Induced Osteoclasts in Rheumatoid Arthritis. Arthritis Rheumatol 73 : 1145-1154, 2021.
9) Elkon KB : Review : Cell Death, Nucleic Acids, and Immunity : Inflammation Beyond the Grave. Arthritis Rheumatol 70 : 805-816, 2018.
10) Lee KH, et al : Neutrophil extracellular traps (NETs) in autoimmune diseases : A comprehensive review. Autoimmun Rev 16 : 1160-1173, 2017.
11) Osada A, et al : Citrullinated inter-alpha-trypsin inhibitor heavy chain 4 in arthritic joints and its potential effect in the neutrophil migration. Clin Exp Immunol 203 : 385-399, 2021.
12) Ohyama A, et al : Specific increase in joint neutrophil extracellular traps and its relation to interleukin 6 in autoimmune arthritis. Int J Mol Sci 22 : 7633, 2021.
13) Kawaguchi H, et al : Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis. Arthritis Res Ther 20 : 66, 2018.
P.94 掲載の参考文献
1) Demoruelle MK, et al : Lung inflammation in the pathogenesis of rheumatoid arthritis. Immunol Rev 294 : 124-132, 2020.
2) Humby F, et al : Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 6 : e1, 2009.
4) Wang Y, et al : Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome highlight T cell-initiated autoimmunity. Ann Rheum Dis 79 : 268-275, 2020.
5) Ye Z, et al : Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation. Nat Commun 12 : 907, 2021.
6) Takeshita M, et al : Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell. Ann Rheum Dis 78 : 1346-1356, 2019.
7) Zhang F, et al : Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol 20 : 928-942, 2019.
8) Schmitt N, et al : The cytokine TGF-β co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat Immunol 15 : 856-865, 2014.
9) Deng J, et al : Signal Transducer and Activator of Transcription 3 Hyperactivation Associates With Follicular Helper T Cell Differentiation and Disease Activity in Rheumatoid Arthritis. Front Immunol 9 : 1226, 2018.
10) Sun Z, et al : The kinase PDK1 is critical for promoting T follicular helper cell differentiation. Elife 10 : e61406, 2021.
11) Ashouri JF, et al : Reporters of TCR signaling identify arthritogenic T cells in murine and human autoimmune arthritis. Proc Natl Acad Sci U S A 116 : 18517-18527, 2019.
12) Sage PT, Sharpe AH : The multifaceted functions of follicular regulatory T cells. Curr Opin Immunol 67 : 68-74, 2020.
13) Liu C, et al : Increased Circulating Follicular Treg Cells Are Associated With Lower Levels of Autoantibodies in Patients With Rheumatoid Arthritis in Stable Remission. Arthritis Rheumatol 70 : 711-721, 2018.
14) Kolios AGA, et al : Interleukin-2 and regulatory T cells in rheumatic diseases. Nat Rev Rheumatol 17 : 749-766, 2021.
15) Hao H, et al : Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin-2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. Arthritis Rheumatol 73 : 132-142, 2021.
16) Meffre E : The establishment of early B cell tolerance in humans : lessons from primary immunodeficiency diseases. Ann N Y Acad Sci 1246 : 1-10, 2011.
17) Iwata S, et al : Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis : a potential target for abatacept therapy. Arthritis Rheumatol 67 : 63-73, 2015.
18) Corneth OBJ, et al : Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. Arthritis Rheumatol 69 : 1313-1324, 2017.
19) Tanaka Y, et al : Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology (Oxford) 60 : 2884-2895, 2021.
20) Ringheim GE, et al : Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases : Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Front Immunol 12 : 662223, 2021.
21) Karnell JL, et al : A CD40 L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci Transl Med 11 : eaar6584, 2019.
22) Schiff M, et al : Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors : results of a randomised, double-blind, placebo-controlled, phase 3 study. RMD Open 1 : e000037, 2015.
23) Cancro MP : Age-Associated B Cells. Annu Rev Immunol 38 : 315-340, 2020.
24) Keller B, et al : The expansion of human T-bethighCD21low B cells is T cell dependent. Sci Immunol 6 : eabh0891, 2021.
25) Nakayama T, et al : Type 1 helper T cells generate CXCL9/10-producing T-bet+ effector B cells potentially involved in the pathogenesis of rheumatoid arthritis. Cell Immunol 360 : 104263, 2021.
26) Banko Z, et al : Induction and Differentiation of IL-10-Producing Regulatory B Cells from Healthy Blood Donors and Rheumatoid Arthritis Patients. J Immunol 198 : 1512-1520, 2017.
P.101 掲載の参考文献
2) Tsukasaki M, Takayanagi H : Osteoimmunology : evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol 19 : 626-642, 2019.
3) Okamoto K, et al : Osteoimmunology : The Conceptual Framework Unifying the Immune and Skeletal Systems. Physiol Rev 97 : 1295-1349, 2017.
6) Diarra D, et al : Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13 : 156-163, 2007.
7) Sun W, et al : B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation. Nat Commun 9 : 5127, 2018.
12) Komatsu N, et al : Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20 : 62-68, 2014.
13) Komatsu N, et al : Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis. J Clin Invest 131 : e143060, 2021.
14) Croft AP, et al : Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570 : 246-251, 2019.
15) Hasegawa T, et al : Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1. Nat Immunol 20 : 1631-1643, 2019.
P.106 掲載の参考文献
1) Nygaard G, Firestein GS : Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol 16 : 316-333, 2020.
2) Matsuo Y, et al : Local fibroblast proliferation but not influx is responsible for synovial hyperplasia in a murine model of rheumatoid arthritis. Biochem Biophys Res Commun 470 : 504-509, 2016.
3) Buechler MB, et al : Cross-tissue organization of the fibroblast lineage. Nature 593 : 575-579, 2021.
4) Mizoguchi F, et al : Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nat Commun 9 : 789, 2018.
5) Croft AP, et al : Distinct fibroblast subsets drive inflammation and damage in arthritis. Nature 570 : 246-251, 2019.
6) Hirota K, et al : Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis. Immunity 48 : 1220-1232.e5, 2018.
7) Danks L, et al : RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis 75 : 1187-1195, 2016.
8) Noda S, et al : CD34+THY1+ synovial fibroblast subset in arthritic joints has high osteoblastic and chondrogenic potentials in vitro. Arthritis Res Ther 24 : 45, 2022.
9) Hosoya T, et al : Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression. Ann Rheum Dis 75 : 253-259, 2016.
10) Svensson MND, et al : Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal. Sci Adv 6 : eaba4353, 2020.
11) Kono M, et al : Ras guanine nucleotide-releasing protein 4 is aberrantly expressed in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and controls their proliferation. Arthritis Rheumatol 67 : 396-407, 2015.
12) Nakamura H, et al : Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis. Ann Rheum Dis 77 : 1765-1772, 2018.
13) Leblond A, et al : Targeting synovial neoangiogenesis in rheumatoid arthritis. Autoimmun Rev 16 : 594-601, 2017.
14) Bordy R, et al : Microvascular endothelial dysfunction in rheumatoid arthritis. Nat Rev Rheumatol 14 : 404-420, 2018.
15) Simon LS, et al : The Jak/STAT pathway : A focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 51 : 278-284, 2021.
16) Jakob MO, et al : Neuro-Immune Circuits Regulate Immune Responses in Tissues and Organ Homeostasis. Front Immunol 11 : 308, 2020.
P.113 掲載の参考文献
1) Holdsworth SR, Gan PY : Cytokines : Names and Numbers You Should Care About. Clin J Am Soc Nephrol 10 : 2243-2254, 2015.
2) Schwartz DM, et al : Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 12 : 25-36, 2016.
3) Smolen JS, et al : Rheumatoid arthritis. Lancet 388 : 2023-2038, 2016.
5) O'Shea JJ, et al : Cytokines and autoimmunity. Nat Rev Immunol 2 : 37-45, 2002.
7) Komatsu N, et al : Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20 : 62-68, 2014.
8) McInnes IB, Schatt G : Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389 : 2328-2337, 2017.
9) Chizzolini C, et al : Cytokines in chronic rheumatic diseases : is everything lack of homeostatic balance? Arthritis Res Ther 11 : 246, 2009.
10) Narisawa M, et al : Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. Bone 142 : 115616, 2021.
11) Tanaka Y, et al : Janus kinase-targeting therapies in rheumatology : a mechanisms-based approach. Nat Rev Rheumatol 18 : 133-145, 2022.
P.119 掲載の参考文献
1) 高崎芳成 : リウマトイド因子. リウマチナビゲーター (中村耕三, ほか編), p72-73, メディカルレビュー社, 2001.
2) 熊谷俊一 : 早期診断に有用な検査とその利用法膠原病・アレルギー疾患. 日本内科学会雑誌 94 : 2545-2551, 2005.
3) 高崎芳成 : 抗CCP抗体-早期RAの診断と予後の予測に役立つか. リウマチ科 41 : 451-458, 2009.
4) van Delft MAM, Huizinga TWJ : An overview of autoantibodies in rheumatoid arthritis. J Autoimmun 110 : 102392, 2020.
5) Masson-Bessiere C, et al : The major synovial targets of the rheumatoid arthritis-specific anti-filaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166 : 4177-4184, 2001.
7) Takasaki Y, et al : Anti-cyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. Mod Rheumatol 14 : 367-375, 2004.
9) Nielen MM, et al : Specific autoantibodies precede the symptoms of rheumatoid arthritis : a study of serial measurements in blood donors. Arthritis Rheum 50 : 380-386, 2004.
10) Kastbom A, et al : Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63 : 1085-1089, 2004.
12) van der Helm-van Mil AH, et al : Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7 : R949-958, 2005.
13) Chatzidionysiou K, et al : Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed : pooled data from 10 European registries. Ann Rheum Dis 70 : 1575-1580, 2011.
14) Gottenberg JE, et al : Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept : data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 71 : 1815-1819, 2012.
15) Matsudaira R, et al : Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 38 : 2346-2354, 2011.
P.123 掲載の参考文献
1) Taylor PC, et al : Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 376 : 652-662, 2017.
2) Fautrel B, et al : Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naive to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs : a matching-adjusted indirect comparison. RMD Open 6 : e001131, 2020.
3) Cook AD, et al : Immune Cytokines and Their Receptors in Inflammatory Pain. Trends Immunol 39 : 240-255, 2018.
4) Cook AD, et al : TNF and granulocyte macrophage-colony stimulating factor interdependence mediates inflammation via CCL17. JCI Insight 3 : e99249, 2018.
5) Wright HL, et al : Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 51 : 451-459, 2012.
6) Buch MH, et al : Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 17 : 17-33, 2021.
7) Ji RR, et al : Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology 129 : 343-366, 2018.
8) Kato M : New insights into IFN-γ in rheumatoid arthritis : role in the era of JAK inhibitors. Immunol Med 43 : 72-78, 2020.
9) Pope JE : Management of Fatigue in Rheumatoid Arthritis. RMD Open 6 : e001084, 2020.
10) Mastorakos G, et al : Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77 : 1690-1694, 1993.
11) Eijsbouts AM, et al : Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. Clin Exp Rheumatol 23 : 658-664, 2005.
12) Rodriguez-Carrio J, et al : Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis : A Potential Limitation for Its Use As a Clinical Biomarker. Front Immunol 8 : 2007, 2017.

III 関節リウマチの検査・診断

P.139 掲載の参考文献
P.144 掲載の参考文献
2) Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 39 : 1-8, 1996.
3) すぐに使えるリウマチ・膠原病診療マニュアル-目で見てわかる, 関節痛・不明熱の鑑別, 治療, 専門科へのコンサルト- (岸本暢将編), 羊土社, 2009.
4) Kelley's Textbook of Rheumatology, 7th ed (ed by Harris E, et al), WB Saunders, Philadelphia, 2004.
5) Mies Richie A, Francis ML : Diagnostic approach to polyarticular joint pain. Am Fam Physician 68 : 1151-1160, 2003.
P.149 掲載の参考文献
1) Turesson C, et al : Extra-articular rheumatoid arthritis : prevalence and mortality. Rheumatology (Oxford) 38 : 668-674, 1999.
2) Singh JA, et al : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64 : 625-639, 2012.
3) Conforti A, et al : Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev 20 : 102735, 2021.
4) Ziff M : The rheumatoid nodule. Arthritis Rheum 33 : 761-767, 1990.
5) Kaye BR, et al : Rheumatoid nodules. Review of the spectrum of associated conditions and proposal of a new classification, with a report of four seronegative cases. Am J Med 76 : 279-292, 1984.
6) Sayah A, et al : Rheumatoid arthritis : a review of the cutaneous manifestations. J Am Acad Dermatol 53 : 191-209 ; quiz 210-212, 2005.
7) Cojocaru M, et al : New insight into the rheumatoid vasculitis. Rom J Intern Med 53 : 128-132, 2015.
8) Feist E, et al : [Diseases of the outer eye in rheumatoid arthritis]. Z Rheumatol 69 : 403-410, 2010.
9) Kotter I, et al : [Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis]. Z Rheumatol 76 : 673-681, 2017.
10) Vignesh AP, et al : Ocular manifestations of rheumatoid arthritis and their correlation with anticyclic citrullinated peptide antibodies. Clin Ophthalmol 9 : 393-397, 2015.
11) 膠原病に伴う間質性肺疾患診断・治療指針 2020 (日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針作成委員会編), p104, 日本呼吸器学会/日本リウマチ学会, 2020.
13) Kadura S, Raghu G : Rheumatoid arthritis-interstitial lung disease : manifestations and current concepts in pathogenesis and management. Eur Respir Rev 30 : 210011, 2021.
14) Turesson C, et al : The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther 7 : R1386-1393, 2005.
15) De Cock D, et al : Malignancy and rheumatoid arthritis : Epidemiology, risk factors and management. Best Pract Res Clin Rheumatol 32 : 869-886, 2018.
P.153 掲載の参考文献
1) 免疫抑制・化学療法により発症するB型肝炎対策ガイドライン (改訂版) (厚生労働省/難治性の肝・胆道疾患に関する調査研究班, 肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究班), 2011年9月26日改定.
2) 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン [2016年改訂版] (日本リウマチ学会MTX 診療ガイドライン策定小委員会編), 羊土社, 2016.
3) 関節リウマチ (RA) に対するTNF阻害薬使用の手引き (2020年2月1日改訂版), 日本リウマチ学会, 2020.
P.158 掲載の参考文献
1) Westergren A : Studies of the suspension stability of the blood in pulmonary tuberculosis. Acta Med Scand 54 : 247-282, 1921.
2) 臨床検査法提要 [改訂第35版] (金井正光監/奥村伸生, ほか編), p492-494, 金原出版, 2020.
3) Nishikawa T, Ashworth JJ : Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 180 : 3492-3501, 2008.
4) Sproston NR, et al : Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol 9 : 754, 2018.
5) 伊藤喜久 : CRPの免疫生理活性機能. 臨床検査 46 : 959-966, 2002.
6) Zeinolabediny Y, et al : Monomeric C-Reactive Protein-A Feature of Inflammatory Disease Associated With Cardiovascular Pathophysiological Complications? In Vivo 35 : 693-697, 2021.
7) Khreiss T, et al : Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109 : 2016-2022, 2004.
8) Ridker PM, Morrow DA : C-reactive protein, inflammation, and coronary risk. Cardiol Clin 21 : 315-325, 2003.
9) 久保木幸司, 芳野原 : 炎症指標と心血管病. Angiology Frontier 8 : 32-40, 2009.
10) McGonagle D, McDermott MF : A proposed classification of the immunological diseases. PLoS Med 3 : e297, 2006.
11) Pope JE, Choy EH : C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum 51 : 219-229, 2021.
P.164 掲載の参考文献
1) Ronnelid J, et al : Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives. Front Immunol 12 : 685312, 2021.
2) Bugatti S, et al : The Clinical Value of Autoantibodies in Rheumatoid Arthritis. Front Med (Lausanne) 5 : 339, 2018.
3) Conigliaro P, et al : Autoantibodies in inflammatory arthritis. Autoimmun Rev 15 : 673-683, 2016.
4) Kakumanu P, et al : Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol 36 : 2682-2690, 2009.
5) Nielen MM, et al : Specific autoantibodies precede the symptoms of rheumatoid arthritis : a study of serial measurements in blood donors. Arthritis Rheum 50 : 380-386, 2004.
6) Figueiredo CP, et al : Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann Rheum Dis 76 : 399-407, 2017.
7) Dekkers JS, et al : Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 58 : 149-153, 2019.
8) Alten R, et al : Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naive : 6-month results from a real-world, international, prospective study. RMD Open 3 : e000345, 2017.
9) Alemao E, et al : Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis : a meta-analysis. Clin Exp Rheumatol 38 : 455-466, 2020.
10) Lv Q, et al : The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis : a meta-analysis. PLoS One 9 : e89442, 2014.
11) Pers YM, et al : Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford) 53 : 76-84, 2014.
12) Courvoisier DS, et al : The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents : results from a collaboration of 16 registries. Rheumatology (Oxford) 60 : 820-828, 2021.
13) De Rycke L, et al : Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64 : 299-302, 2005.
14) Jansen DTSL, et al : Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission : post hoc analysis of the AGREE study. RMD Open 4 : e000564, 2018.
15) Nakashima R, et al : The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 9 : e85062, 2014.
P.170 掲載の参考文献
1) Ishiguro N, et al : Mechanism of cartilage destruction in osteoarthritis. Nagoya J Med Sci 65 : 73-84, 2002.
2) Aletaha D, et al : Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis 70 : 733-739, 2011.
3) Ishiguro N, et al : Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 44 : 2503-2511, 2001.
4) Hughes C, et al : Metalloproteinase digestion of cartilage proteoglycan. Pattern of cleavage by stromelysin and susceptibility to collagenase. Biochem J 279 (Pt 3) : 733-739, 1991.
5) Ma JD, et al : Continuously elevated serum matrix metalloproteinase-3 for 3-6 months predict one-year radiographic progression in rheumatoid arthritis : a prospective cohort study. Arthritis Res Ther 17 : 289, 2015.
6) Kaneko A, et al : Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index) : CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 32 : 3631-3637, 2012.
7) Hattori Y, et al : Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis. Mod Rheumatol 28 : 242-248, 2018.
8) マトリックスメタロプロテイナーゼ-3キット パナクリア(R) MMP-3「プレート」添付文書, 積水メディカル株式会社, 2017年1月改訂 (第10版).
9) Rubin DA : MRI and ultrasound of the hands and wrists in rheumatoid arthritis. I. Imaging findings. Skeletal Radiol 48 : 677-695, 2019.
10) Lerner A, et al : MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. Best Pract Res Clin Rheumatol 32 : 550-562, 2018.
11) Zhou L, et al : Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis. Arthritis Res Ther 19 : 250, 2017.
12) Hattori Y, et al : Normal serum matrix metalloproteinase-3 levels can be used to predict clinical remission and normal physical function in patients with rheumatoid arthritis. Clin Rheumatol 38 : 181-187, 2019.
13) Hattori Y, et al : High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab. Mod Rheumatol 28 : 119-125, 2018.
14) Urata Y, et al : Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients : T-4 Study. Ann Rheum Dis 71 : 534-540, 2012.
P.175 掲載の参考文献
1) リウマチ診療のための関節エコー撮像法ガイドライン (日本リウマチ学会関節リウマチ超音波標準化委員会編), 羊土社, 2011.
2) Yoshida H, et al : Relationship between pre-radiographic cartilage damage following anterior cruciate ligament injury and biomarkers of cartilage turnover in clinical practice : a cross-sectional observational study. Osteoarthritis Cartilage 21 : 831-838, 2013.
P.180 掲載の参考文献
1) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
2) Ory PA : Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 62 : 597-604, 2003.
3) Aletaha D, et al : 2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 : 2569-2581, 2010.
4) Arnett FC, et al : The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 : 315-324, 1988.
5) 松下功 : 関節リウマチの画像診断. 臨床リウマチ 31 : 88-97, 2019.
6) 布留守敏 : 単純X線. 日本臨牀 72 (増刊 : 最新関節リウマチ学) : 237-252, 2014.
7) Hinck VC, Hopkins CE : Measurement of the atlanto-dental interval in the adult. Am J Roentgenol Radium Ther Nucl Med 84 : 945-951, 1960.
8) Steinbrocker O, et al : Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 140 : 659-662, 1949.
9) Larsen A, et al : Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18 : 481-491, 1977.
10) van der Heijde DM : Plain X-rays in rheumatoid arthritis : overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10 : 435-453, 1996.
11) van der Heijde DM, et al : Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 : 1036-1038, 1989.
12) Sharp JT, et al : Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14 : 706-720, 1971.
13) Sharp JT, et al : How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28 : 1326-1335, 1985.
14) Landewe R, van der Heijde D : Radiographic progression depicted by probability plots : presenting data with optimal use of individual values. Arthritis Rheum 50 : 699-706, 2004.
15) 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン 2016年改訂版 (日本リウマチ学会MTX診療ガイドライン策定小委員会編), 羊土社, 2016.
P.186 掲載の参考文献
2) van Steenbergen HW, et al : Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis 75 : 1824-1830, 2016.
4) Nakagomi D, et al : Ultrasound can improve the accuracy of the 2010 American College of Rheumatology/European League against rheumatism classification criteria for rheumatoid arthritis to predict the requirement for methotrexate treatment. Arthritis Rheum 65 : 890-898, 2013.
5) Smolen JS, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 : 3-15, 2016.
6) Haavardsholm EA, et al : Ultrasound in management of rheumatoid arthritis : ARCTIC randomised controlled strategy trial. BMJ 354 : i4205, 2016.
7) Iwamoto T, et al : Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission : high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation. Arthritis Care Res (Hoboken) 66 : 1576-1581, 2014.
P.189 掲載の参考文献
1) Lindqvist E, et al : Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 62 : 611-616, 2003.
2) Axelsen MB, et al : Reliability and responsiveness of dynamic contrast-enhanced magnetic resonance imaging in rheumatoid arthritis. Scand J Rheumatol 42 : 115-122, 2013.
3) Ejbjerg B, et al : Magnetic resonance imaging of wrist and finger joints in healthy subjects occasionally shows changes resembling erosions and synovitis as seen in rheumatoid arthritis. Arthritis Rheum 50 : 1097-1106, 2004.
4) McQueen FM, et al : High-grade MRI bone oedema is common within the surgical field in rheumatoid arthritis patients undergoing joint replacement and is associated with osteitis in subchondral bone. Ann Rheum Dis 66 : 1581-1587, 2007.
6) Baker JF, et al : Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis : secondary analysis from a large clinical trial. Ann Rheum Dis 73 : 1968-1974, 2014.
8) Ostergaard M, et al : OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 30 : 1385-1386, 2003.
9) McQueen F, et al : OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR Imaging Module. J Rheumatol 30 : 1387-1392, 2003.
10) Suzuki T, et al : A new low-field extremity magnetic resonance imaging and proposed compact MRI score : evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. Mod Rheumatol 19 : 358-365, 2009.
11) Frenken M, et al : The value of the simplified RAMRIS-5 in early RA patients under methotrexate therapy using high-field MRI. Arthritis Res Ther 21 : 21, 2019.
P.194 掲載の参考文献
1) Tsukasaki M, Takayanagi H : Osteoimmunology : evolving concepts in bone-immune interactions in health and disease. Nat Rev Immunol 19 : 626-642, 2019.
2) Yamanaka H, et al : Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol 24 : 33-40, 2014.
4) Manolagas SC : Birth and death of bone cells : basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 : 115-137, 2000.
5) Saito M, Marumo K : Effects of Collagen Crosslinking on Bone Material Properties in Health and Disease. Calcif Tissue Int 97 : 242-261, 2015.
6) Tanaka Y : Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis : An Overview. J Clin Med 10 : 1241, 2021.
7) Zhu TY, et al : Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis : a case-control study with HR-pQCT. J Bone Miner Res 29 : 2118-2129, 2014.
8) Kleyer A, et al : Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73 : 854-860, 2014.
9) Takeuchi T, et al : Role of interleukin-6 in bone destruction and bone repair in rheumatoid arthritis. Autoimmun Rev 20 : 102884, 2021.
10) Maeda K, et al : Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18 : 405-412, 2012.
11) Maeda K, et al : The Regulation of Bone Metabolism and Disorders by Wnt Signaling. Int J Mol Sci 20 : 5525, 2019.
12) Komori T : Glucocorticoid Signaling and Bone Biology. Horm Metab Res 48 : 755-763, 2016.
13) 骨評価. 骨粗鬆症の予防と治療ガイドライン 2015年版 (骨粗鬆症の予防と治療ガイドライン作成委員会編), p26-29, 日本骨粗鬆症学会/日本骨代謝学会/骨粗鬆症財団, 2015.
14) 漆原信夫 : 骨粗鬆症におけるイバンドロネート静注製剤の安全性 (他のBP製剤と比較して) および有効性の検討-急性期反応, 上部消化管障害, 患者アンケート結果, 橈骨遠位1/3, 1/6, 1/10部位骨密度を中心に. 新薬と臨牀 65 : 812-825, 2016.
15) Imoto Y, et al : Effects of abnormal collagen crosslinks on hypersonic longitudinal wave velocity in bovine cortical bone. Glycative Stress Research 2 : 101-107, 2015.
16) Marotte H, et al : A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther 9 : R61, 2007.
17) Chopin F, et al : Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67 : 353-357, 2008.
19) Krieckaert CL, et al : Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis : a cohort study. Rheumatology (Oxford) 52 : 547-553, 2013.
20) Gulyas K, et al : Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39 : 167-175, 2020.
21) Orsolini G, et al : Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis. Calcif Tissue Int 98 : 580-585, 2016.
22) Abu-Shakra M, et al : Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis. Isr Med Assoc J 20 : 239-244, 2018.
23) Briot K, et al : The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine 82 : 109-115, 2015.
24) Finzel S, et al : Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis 78 : 1186-1191, 2019.
25) Tada M, et al : Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice : AIRTIGHT study. Rheumatol Int 38 : 777-784, 2018.
26) Hamar A, et al : Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int 32 : 1621-1629, 2021.
27) Adam S, et al : JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med 12 : eaay4447, 2020.
28) Gaber T, et al : Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. Int J Mol Sci 21 : 865, 2020.
29) Kawai VK, et al : Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases. Arthritis Care Res (Hoboken) 65 : 1085-1094, 2013.
P.201 掲載の参考文献
1) Klemperer P, et al : Diffuse collagen disease : acute disseminated lupus erythematosus and diffuse scleroderma. JAMA 119 : 331-332, 1942.
2) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
3) van der Heijde DM : Plain X-rays in rheumatoid arthritis : overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 10 : 435-453, 1996.
4) Barnabe C, et al : Quantification of small joint space width, periarticular bone microstructure and erosions using high-resolution peripheral quantitative computed tomography in rheumatoid arthritis. Clin Exp Rheumatol 31 : 243-250, 2013.
5) Regensburger A, et al : A comparative analysis of magnetic resonance imaging and high-resolution peripheral quantitative computed tomography of the hand for the detection of erosion repair in rheumatoid arthritis. Rheumatology (Oxford) 54 : 1573-1581, 2015.
6) Finzel S, et al : Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis 78 : 1186-1191, 2019.
7) Burghardt AJ, et al : Quantitative in vivo HR-pQCT imaging of 3D wrist and metacarpophalangeal joint space width in rheumatoid arthritis. Ann Biomed Eng 41 : 2553-2564, 2013.
8) Raghu G, et al : Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198 : e44-e68, 2018.
9) du Bois RM : An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 21 : 141-146, 2012.
10) Oldham JM, et al : Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 47 : 1767-1775, 2016.
11) 若原恵子 : 関節リウマチ ; 各種疾患にみられる呼吸器病変. 自己免疫疾患. 別冊日本臨牀領域別症候群シリーズ No.19 呼吸器症候群 (第3版) III, p308-312, 日本臨牀社, 2021.
12) Wang D, et al : Mechanisms of lung disease development in rheumatoid arthritis. Nat Rev Rheumatol 15 : 581-596, 2019.
15) 膠原病に伴う間質性肺疾患診断・治療指針2020 (日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針 2020 作成委員会編), 日本呼吸器学会/日本リウマチ学会, 2020.
P.206 掲載の参考文献
1) Aletaha D, Smolen JS : Diagnosis and Management of Rheumatoid Arthritis : A Review. JAMA 320 : 1360-1372, 2018.
2) Ropes MW, et al : Proposed diagnostic criteria for rheumatoid arthritis. Ann Rheum Dis 16 : 118-125, 1957.
3) Arnett FC, et al : The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 : 315-324, 1988.
4) Aletaha D, et al : 2010 Rheumatoid arthritis classification criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62 : 2569-2581, 2010.
7) Neogi T, et al : The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis : Phase 2 methodological report. Arthritis Rheum 62 : 2582-2591, 2010.
8) van der Linden MP, et al : Classification of rheumatoid arthritis : comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum 63 : 37-42, 2011.
P.211 掲載の参考文献
2) Scott DG, et al : Systemic rheumatoid vasculitis : a clinical and laboratory study of 50 cases. Medicine (Baltimore) 60 : 288-297, 1981.
4) 難病情報センターホームページ : 悪性関節リウマチ. [https://www.nanbyou.or.jp/entry/205] (2022年3月閲覧)
5) Bywaters EG : A Variant of Rheumatoid Arthritis resembling Palindromic Rheumatism. Ann Rheum Dis 8 : 1-30, 1949.
8) Turesson C, Jacobsson LTH : Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 33 : 65-72, 2004.
9) Felty AR : Chronic arthritis in the adult associated with splenomegaly and leukopenia. Bull Johns Hopkins Hosp 35 : 16-20, 1924.
10) Bowman SJ : Hematological manifestations of rheumatoid arthritis. Scand J Rheumatol 31 : 251-259, 2002.
11) Owlia MB, et al : Felty's Syndrome, Insights and Updates. Open Rheumatol J 8 : 129-136, 2014.
P.217 掲載の参考文献
1) Petty RE, et al : International League of Associations for Rheumatology classification of juvenile idiopathic arthritis : second revision, Edmonton, 2001. J Rheumatol 31 : 390-392, 2004.
2) Martini A, et al : Toward New Classification Criteria for Juvenile Idiopathic Arthritis : First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 46 : 190-197, 2019.
3) Still GF : On a Form of Chronic Joint Disease in Children. Med Chir Trans 80 : 47-60.9, 1897.
4) Kumar S, et al : Application of the Yamaguchi criteria for classification of "suspected" systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J 10 : 40, 2012.
5) Yamaguchi M, et al : Preliminary criteria for classification of adult Still's disease. J Rheumatol 19 : 424-430, 1992.
6) 岡本奈美 : 若年性特発性関節炎. 小児科 58 : 441-450, 2017.
7) Bywaters EG : Still's disease in the adult. Ann Rheum Dis 30 : 121-133, 1971.
8) Inoue N, et al : Cytokine profile in adult-onset Still's disease : Comparison with systemic juvenile idiopathic arthritis. Clin Immunol 169 : 8-13, 2016.
9) Hinks A, et al : Brief Report : The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70 : 957-962, 2018.
10) Colbert RA : Classification of juvenile spondyloarthritis : Enthesitis-related arthritis and beyond. Nat Rev Rheumatol 6 : 477-485, 2010.
11) Yasumura J, et al : Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan : first report of the pediatric rheumatology association of Japan (PRAJ). Pediatr Rheumatol Online J 17 : 15, 2019.
12) Mizuta M, et al : Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 60 : 2421-2426, 2021.
P.221 掲載の参考文献
1) Winthrop KL, et al : Unmet need in rheumatology : reports from the Targeted Therapies meeting 2019. Ann Rheum Dis 79 : 88-93, 2020.
2) Aletaha D, et al : Attitudes to early rheumatoid arthritis : changing patterns. Results of a survey. Ann Rheum Dis 63 : 1269-1275, 2004.
3) Anderson JJ, et al : Factors predicting response to treatment in rheumatoid arthritis : the importance of disease duration. Arthritis Rheum 43 : 22-29, 2000.
4) van der Woude D, et al : Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis : results from two large early arthritis cohorts. Arthritis Rheum 60 : 2262-2271, 2009.
5) Ten Klooster PM, et al : Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy. Clin Rheumatol 38 : 2727-2736, 2019.
6) Puolakka K, et al : Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis : five-year experience from the FIN-RACo trial. Arthritis Rheum 52 : 36-41, 2005.
7) van der Linden MP, et al : Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 62 : 3537-3546, 2010.
8) van Steenbergen HW, et al : EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 76 : 491-496, 2017.
9) van Dongen H, et al : Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis : a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 56 : 1424-1432, 2007.
10) Hallert E, et al : Rheumatoid arthritis is still expensive in the new decade : a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09. Scand J Rheumatol 45 : 371-378, 2016.
11) McWilliams DF, et al : Work disability and state benefit claims in early rheumatoid arthritis : the ERAN cohort. Rheumatology (Oxford) 53 : 473-481, 2014.
12) Serhal L, et al : Rheumatoid arthritis in the elderly : Characteristics and treatment considerations. Autoimmun Rev 19 : 102528, 2020.
13) Roodenrijs NMT, et al : Characteristics of difficult-to-treat rheumatoid arthritis : results of an international survey. Ann Rheum Dis 77 : 1705-1709, 2018.
14) Nagy G, et al : EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80 : 31-35, 2021.
15) Ochi S, et al : Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs : a retrospective cohort study from the FIRST registry. Clin Exp Rheumatol, 2021. (Epub ahead of print)
P.225 掲載の参考文献
2) van der Heijde DM, et al : Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20 : 579-581, 1993.
3) Prevoo ML, et al : Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 : 44-48, 1995.
4) Smolen JS, et al : A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42 : 244-257, 2003.
6) Aletaha D, et al : Remission and active disease in rheumatoid arthritis : defining criteria for disease activity states. Arthritis Rheum 52 : 2625-2636, 2005.
P.231 掲載の参考文献
1) Bartlett SJ, et al : Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence : qualitative results. Rheumatology (Oxford) 59 : 1662-1670, 2020.
2) Bruce B, et al : The Stanford Health Assessment Questionnaire : a review of its history, issues, progress, and documentation. J Rheumatol 30 : 167-178, 2003.
3) Pincus T, et al : Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 26 : 1346-1353, 1983.
4) Pincus T, et al : Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol 23 : S19-28, 2005.
5) Fatima S, et al : Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis. Arthritis Rheumatol 73 : 197-202, 2021.
6) Pincus T, et al : RAPID3-an index of physical function, pain, and global status as "vital signs" to improve care for people with chronic rheumatic diseases. Bull NYU Hosp Jt Dis 67 : 211-225, 2009.
7) Pincus T, et al : RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria : Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) 63 : 1142-1149, 2011.
8) Boone NW, et al : Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. RMD Open 5 : e001050, 2019.
10) Ware JE Jr, et al : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 : 473-483, 1992.
11) Cella D, et al : Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32 : 811-819, 2005.
12) Pope JE : Management of Fatigue in Rheumatoid Arthritis. RMD Open 6 : e001084, 2020.
13) Zhang W, et al : Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. Arthritis Res Ther 12 : R177, 2010.
15) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
P.239 掲載の参考文献
1) Tanaka S : Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World J Orthop 4 : 1-6, 2013.
2) Drossaers-Bakker KW, et al : Long-term course and outcome of functional capacity in rheumatoid arthritis : the effect of disease activity and radiologic damage over time. Arthritis Rheum 42 : 1854-1860, 1999.
3) Genant HK : Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 75 : 35-47, 1983.
4) Larsen A, et al : Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 18 : 481-491, 1977.
5) Sharp JT, et al : Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 14 : 706-720, 1971.
6) Sharp JT, et al : Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 28 : 16-24, 1985.
7) van der Heijde DM, et al : Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 : 1036-1038, 1989.
8) van der Heijde D, et al : Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 38 : 941-947, 1999.
9) Genant HK, et al : Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 41 : 1583-1590, 1998.
10) Conaghan P, et al : Magnetic resonance imaging in rheumatoid arthritis : summary of OMERACT activities, current status, and plans. J Rheumatol 28 : 1158-1162, 2001.
11) Ostergaard M, et al : The OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging (MRI) Scoring System : Updated Recommendations by the OMERACT MRI in Arthritis Working Group. J Rheumatol 44 : 1706-1712, 2017.
12) Haavardsholm EA, et al : Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis : bone marrow oedema predicts erosive progression. Ann Rheum Dis 67 : 794-800, 2008.
13) Hetland ML, et al : MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 68 : 384-390, 2009.
15) Tanaka N, et al : Synovial membrane enhancement and bone erosion by magnetic resonance imaging for prediction of radiologic progression in patients with early rheumatoid arthritis. Rheumatol Int 25 : 103-107, 2005.
P.244 掲載の参考文献
3) Iidaka T, et al : Prevalence of radiographic hip osteoarthritis and its association with hip pain in Japanese men and women : the ROAD study. Osteoarthritis Cartilage 24 : 117-123, 2016.
4) Kodama R, et al : Prevalence of hand osteoarthritis and its relationship to hand pain and grip strength in Japan : The third survey of the ROAD study. Mod Rheumatol 26 : 767-773, 2016.
5) Hada S, et al : Association of medial meniscal extrusion with medial tibial osteophyte distance detected by T2 mapping MRI in patients with early-stage knee osteoarthritis. Arthritis Res Ther 19 : 201, 2017.
6) Tachmazidou I, et al : Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet 51 : 230-236, 2019.
7) Bannuru RR, et al : OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 27 : 1578-1589, 2019.
8) McAlindon TE, et al : Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis : A Randomized Clinical Trial. JAMA 317 : 1967-1975, 2017.
9) Jo CH, et al : Intra-articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee : A 2-Year Follow-up Study. Am J Sports Med 45 : 2774-2783, 2017.
P.255 掲載の参考文献
1) Rudwaleit M, et al : The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I) : classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68 : 770-776, 2009.
5) van der Linden S, et al : Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 : 361-368, 1984.
6) Lambert RG, et al : Defining active sacroiliitis on MRI for classification of axial spondyloarthritis : update by the ASAS MRI working group. Ann Rheum Dis 75 : 1958-1963, 2016.
7) Rudwaleit M, et al : The challenge of diagnosis and classification in early ankylosing spondylitis : do we need new criteria? Arthritis Rheum 52 : 1000-1008, 2005.
8) Garg N, et al : The concept of spondyloarthritis : where are we now? Best Pract Res Clin Rheumatol 28 : 663-672, 2014.
9) 脊椎関節炎診療の手引き 2020 (日本脊椎関節炎学会, 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「強直性脊椎炎に代表される脊椎関節炎の疫学調査・診断基準作成と診療ガイドライン策定を目指した大規模多施設研究」班編), 診断と治療社, 2020.
10) Kameda H, et al : Non-radiographic axial spondyloarthritis. Mod Rheumatol 31 : 277-282, 2021.
11) 朝比奈昭彦, ほか : 日本皮膚科学会ガイドライン乾癬性関節炎診療ガイドライン 2019. 日本皮膚科学会雑誌 129 : 2675-2733, 2019.
12) Veale DJ, Fearon U : The pathogenesis of psoriatic arthritis. Lancet 391 : 2273-2284, 2018.
14) Coates LC, et al : Effect of tight control of inflammation in early psoriatic arthritis (TICOPA) : a UK multicentre, open-label, randomised controlled trial. Lancet 386 : 2489-2498, 2015.
15) Helliwell PS : Axial disease in psoriatic arthritis. Rheumatology (Oxford) 59 : 1193-1195, 2020.
17) Ahvonen P, et al : Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand 15 : 232-253, 1969.
18) Sieper J, et al : Report on the Fourth International Workshop on Reactive Arthritis. Arthritis Rheum 43 : 720-734, 2000.
19) Selmi C, Gershwin ME : Diagnosis and classification of reactive arthritis. Autoimmun Rev 13 : 546-549, 2014.
20) Fragoulis GE, et al : Inflammatory bowel diseases and spondyloarthropathies : From pathogenesis to treatment. World J Gastroenterol 25 : 2162-2176, 2019.
21) Reveille JD : Genetics of spondyloarthritis--beyond the MHC. Nat Rev Rheumatol 8 : 296-304, 2012.
23) McGonagle DG, et al : The role of IL-17A in axial spondyloarthritis and psoriatic arthritis : recent advances and controversies. Ann Rheum Dis 78 : 1167-1178, 2019.
24) Cuthbert RJ, et al : Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis 78 : 1559-1565, 2019.
25) Gravallese EM, Schett G : Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14 : 631-640, 2018.
27) Ward MM, et al : 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71 : 1599-1613, 2019.
28) Haroon N, et al : The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65 : 2645-2654, 2013.
29) Sieper J, et al : The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 15 : 747-757, 2019.
30) Coates LC, et al : Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68 : 1060-1071, 2016.
31) Singh JA, et al : Special Article : 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 71 : 5-32, 2019.
32) Gossec L, et al : EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2019 update. Ann Rheum Dis 79 : 700-712, 2020.
P.262 掲載の参考文献
1) Selmi C, Gershwin ME : Diagnosis and classification of reactive arthritis. Autoimmun Rev 13 : 546-549, 2014.
2) Hannu T : Reactive arthritis. Best Pract Res Clin Rheumatol 25 : 347-357, 2011.
3) Colatutto D, et al : Post-COVID-19 Arthritis and Sacroiliitis : Natural History with Longitudinal Magnetic Resonance Imaging Study in Two Cases and Review of the Literature. Viruses 13 : 1558, 2021.
4) Braun J, et al : On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. J Rheumatol 27 : 2185-2192, 2000.
5) Marks M, Marks JL : Viral arthritis. Clin Med (Lond) 16 : 129-134, 2016.
6) Mathews CJ, et al : Bacterial septic arthritis in adults. Lancet 375 : 846-855, 2010.
P.269 掲載の参考文献
1) Janssens HJEM, et al : A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 170 : 1120-1126, 2010.
3) 高尿酸血症・痛風の治療ガイドライン 第3版 [2022年追補版] (日本痛風・尿酸核酸学会ガイドライン改訂委員会編), 診断と治療社, 2022.
4) Maravic M, Ea HK : Hospital burden of gout, pseudogout and other crystal arthropathies in France. Joint Bone Spine 82 : 326-329, 2015.
5) Zhang W, et al : European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I : terminology and diagnosis. Ann Rheum Dis 70 : 563-570, 2011.
6) Pascual E, et al : Synovial fluid analysis for crystals. Curr Opin Rheumatol 23 : 161-169, 2011.
7) Frediani B, et al : Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease : ultrasonographic criteria proposed. Ann Rheum Dis 64 : 638-640, 2005.
8) Zhang W, et al : EULAR recommendations for calcium pyrophosphate deposition. Part II : management. Ann Rheum Dis 70 : 571-575, 2011.
9) Parperis K, et al : Management of calcium pyrophosphate crystal deposition disease : A systematic review. Semin Arthritis Rheum 51 : 84-94, 2021.
P.273 掲載の参考文献
1) Klemperer P : The concept of collagen diseases. Am J Pathol 26 : 505-519, 1950.
2) Grossman JM : Lupus arthritis. Best Pract Res Clin Rheumatol 23 : 495-506, 2009.
3) Labowitz R, Schumacher HR Jr : Articular manifestations of systemic lupus erythematosus. Ann Intern Med 74 : 911-921, 1971.
4) Goldenberg DL, Cohen AS : Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. Medicine (Baltimore) 57 : 239-252, 1978.
6) Pipili C, et al : Deforming arthropathy in systemic lupus erythematosus. Eur J Intern Med 19 : 482-487, 2008.
7) Reilly PA, et al : Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol 17 : 777-784, 1990.
8) Schur PH : Systemic lupus erythematosus. In : Cecil-Loeb Textbook of Medicine, 13th ed (ed by Beeson PB, McDermott W), p821, WB Saunders, Philadelphia, 1971.
9) Panush RS, et al : 'Rhupus' syndrome. Arch Intern Med 148 : 1633-1636, 1988.
10) Tani C, et al : Rhupus syndrome : assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev 12 : 537-541, 2013.
11) Iagnocco A, et al : Wrist joint involvement in systemic lupus erythematosus. An ultrasonographic study. Clin Exp Rheumatol 22 : 621-624, 2004.
12) Boutry N, et al : MR imaging findings in hands in early rheumatoid arthritis : comparison with those in systemic lupus erythematosus and primary Sjogren syndrome. Radiology 236 : 593-600, 2005.
13) Marguerie C, et al : Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77 : 1019-1038, 1990.
14) Kurtzman DJB, Vleugels RA : Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis : A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 78 : 776-785, 2018.
15) 片山昌紀, 三森経世 : 全身性硬化症・混合性結合組織病. 日本内科学会雑誌 99 : 2407-2413, 2010.
16) Rodnan GP : The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 56 : 422-439, 1962.
P.278 掲載の参考文献
5) Moosig F, et al : Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica : a quantitative PET study. Ann Rheum Dis 63 : 870-873, 2004.
6) Weyand CM, Goronzy JJ : Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 139 : 505-515, 2003.
9) Smets P, et al : Vascular endothelial growth factor levels and rheumatic diseases of the elderly. Arthritis Res Ther 18 : 283, 2016.
10) Yao Q, et al : Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum 40 : 89-94, 2010.
12) Kirino Y, et al : Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet's disease : a retrospective observational study. Arthritis Res Ther 18 : 217, 2016.
13) Frikha F, et al : Destructive arthritis in Behcet's disease : a report of eight cases and literature review. Int J Rheum Dis 12 : 250-255, 2009.
15) 立花暉夫 : サルコイドーシスの全国臨床統計. 日本臨牀 52 : 1508-1515, 1994.
P.283 掲載の参考文献
1) 線維筋痛症診療ガイドライン 2017 (日本線維筋痛症学会, 日本医療研究開発機構線維筋痛症研究班編), p10-17, 日本医事新報社, 2017.
2) Nakatomi Y, et al : Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis : An 11C- (R) -PK11195 PET Study. J Nucl Med 55 : 945-950, 2014.
3) Goebel A, et al : Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest 131 : e144201, 2021.
4) Macchioni P, et al : Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome : The ULISSE Study. J Rheumatol 46 : 904-911, 2019.
5) Wolfe F, et al : The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33 : 160-172, 1990.
6) Wolfe F, et al : 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 46 : 319-329, 2016.
7) Marchesoni A, et al : The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford) 57 : 32-40, 2018.
8) Mornet E : Hypophosphatasia. Metabolism 82 : 142-155, 2018.
9) Leblanc DR, et al : The effect of estrogen on tendon and ligament metabolism and function. J Steroid Biochem Mol Biol 172 : 106-116, 2017.
10) Hyder T, et al : Aromatase Inhibitor-Associated Musculoskeletal Syndrome : Understanding Mechanisms and Management. Front Endocrinol (Lausanne) 12 : 713700, 2021.
11) Murphy AJ, et al : Estradiol suppresses NF-κB activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. J Immunol 184 : 5029-5037, 2010.
12) Orellana C, et al : Postmenopausal hormone therapy and the risk of rheumatoid arthritis : results from the Swedish EIRA population-based case-control study. Eur J Epidemiol 30 : 449-457, 2015.
13) Miyachi K, et al : Anti-DFS70 autoantibodies in Japanese women at different menstrual stages. J Rheumatol Res 1 : 24-32, 2019.
14) Henry NL, et al : A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116 : 4360-4367, 2010.
15) Miyachi K, et al : The treatment of women with post-menopausal undifferentiated arthralgia-the first report of efficacy of hormone replacement therapy. Am J Biomed Sci & Res 1 : 124-129, 2019.

IV 関節リウマチの治療

P.291 掲載の参考文献
1) 竹内勤 : 関節リウマチ. 日本内科学会雑誌 99 : 2392-2400, 2010.
2) 竹内勤 : 関節リウマチの治療の進歩. 日本内科学会雑誌 101 : 647-653, 2012.
3) 竹内勤 : 関節リウマチ診療の軌跡と新たな潮流. 日本内科学会雑誌 109 : 1669-1684, 2020.
4) Smolen JS, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 : 3-15, 2016.
5) 竹内勤 : 関節リウマチ : 診断と治療法の進歩. 日本内科学会雑誌 101 : 2815-2817, 2012.
6) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69 : 964-975, 2010.
7) Takeuchi T, Kameda H : The Japanese experience with biologic therapies for Rheumatoid Arthritis. Nat Rev Rheumatol 6 : 644-652, 2010.
8) Burmester GR, et al : Managing rheumatic and musculoskeletal diseases-past, present and future. Nat Rev Rheumatol 13 : 443-448, 2017.
9) Takeuchi T : Treatment of rheumatoid arthritis with biological agents-as a typical and common immune-mediated inflammatory disease. Proceedings of the Japan Academy, series B 93 : 600-608, 2017.
P.297 掲載の参考文献
1) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
2) 相原守夫 : 診療ガイドラインのためのGRADEシステム [第3版], 中外医学社, 2018.
4) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
P.303 掲載の参考文献
1) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
2) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69 : 964-975, 2010.
3) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. Ann Rheum Dis 76 : 960-977, 2017.
4) Taylor PC, et al : Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 376 : 652-662, 2017.
5) Fleischmann R, et al : Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate : Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol 71 : 1788-1800, 2019.
6) Fleischmann R, et al : Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy) : a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390 : 457-468, 2017.
7) Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis (sponsored by Pfizer), ClinicalTrials.gov, 2019. [https://clinicaltrials.gov/ct2/show/NCT02092467] (2022年3月閲覧)
8) van Mulligen E, et al : Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis : first-year results of the randomised controlled TARA study. Ann Rheum Dis 78 : 746-753, 2019.
9) Nagy G, et al : EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 81 : 20-33, 2022.
10) Fraenkel L, et al : 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 73 : 1108-1123, 2021.
11) Singh JA, et al : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68 : 1-26, 2016.
12) Alten R, Mischkewitz M : 2021 ACR guideline reflects changes in RA treatment. Nat Rev Rheumatol 17 : 513-514, 2021.
P.311 掲載の参考文献
1) 日本製薬工業協会 : 日本の薬事行政第4 章 : 医薬品の製造販売後の調査等と安全管理. [https://www.jpma.or.jp/news_room/issue/yakuji/index.html] (2022年3月閲覧)
2) 独立行政法人医薬品医療機器総合機構 (PMDA). [https://www.pmda.go.jp/about-pmda/outline/0001.html] (2022年3月閲覧)
5) Yamanaka H, et al : Three-year safety and two-year effectiveness of etanercept in patients with rheumatoid arthritis in Japan : Results of long-term postmarketing surveillance. Mod Rheumatol 29 : 737-746, 2019.
6) Koike T, et al : Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : interim analysis of 3881 patients. Ann Rheum Dis 70 : 2148-2151, 2011.
7) Yamamoto K, et al : Longterm Safety of Tocilizumab : Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J Rheumatol 42 : 1368-1375, 2015.
8) Tamura N, et al : Malignancy in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib : Interim Analysis of All-Case Post-Marketing Surveillance. 2018 ACR/ARP Annual Meeting, Chicago, October, 2018.
9) Tamura N, et al : Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib : Interim All-Case Post-Marketing Surveillance. 2018 ACR/ARP Annual Meeting, Chicago, October, 2018.
10) Fujii T, et al : Safety of baricitinib (Bari) in patients with rheumatoid arthritis (RA) : interim report from all case post marketing study in clinical use. The 65th Annual Scientific Meeting of the Japan College of Rheumatology, Kobe, April, 2021.
11) Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ(R) (tofacitinib) in Subjects with Rheumatoid Arthritis (RA). [https://www.pfizer.com/news/press-release/press-release-detail/Pfizer-shares-co-primary-endpoint-results-post-marketing] (2022年1月閲覧)
12) European Medicines Agency : Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 June 2021. [https://www.ema.europa.eu/en/news/meeting-highlightspharmacovigilance-risk-assessment-committee-prac-7-10-june-2021] (2022年3月閲覧)
13) European Medicines Agency : DHPC (Direct Healthcare Professional Communication) : Xeljanz (tofacitinib) : increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors. [https://www.ema.europa.eu/en/medicines/dhpc/xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-malignancies-use-tofacitinib] (2022年3月閲覧)
14) U. S. Food and Drug Administration : FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions-Approved uses also being limited to certain patients. [https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heartrelated-events-cancer-blood-clots-and-death] (2022年3月閲覧)
15) 日本リウマチ学会 : [医薬・医療情報]抗リウマチ薬トファシチニブ (商品名ゼルヤンツ(R)) について (医療関係者向け情報). [https://www.ryumachi-jp.com/publish/iyaku/news210618/] (2022年1月閲覧)
16) Miyasaka N, et al : Guidelines for proper use of etanercept in Japan. Mod Rheum atol 16 : 63-67, 2006.
18) Koike R, et al : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : Postmarketing surveillance report of 7740 patients. Mod Rheumatol 24 : 390-398, 2014.
P.317 掲載の参考文献
1) Okahata A, et al : Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor 1 Predicts the Changes of Rheumatoid Factor Titers in Rheumatoid Arthritis. J Clin Rheumatol 26 : 295-300, 2020.
2) Hashimoto M, et al : Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients. PLoS One 10 : e0122121, 2015.
3) 成田和子 : リウマチの治療と生活療法-組み合わせ自由な新レシピ付き, p115, 日東書院本社, 2006.
4) よくわかる最新医学新版リウマチ (吉野槇一監), p118-121, 主婦の友社, 2005.
5) 2020年リウマチ白書-リウマチ患者の実態 (資料編), p70, 日本リウマチ友の会, 2021.
6) Walsh DA, Mcwilliams DF : Pain in rheumatoid arthritis. Curr Pain Headache Rep 16 : 509-517, 2012.
7) Nakagami Y, et al : Effect of Physical State on Pain Mediated Through Emotional Health in Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 71 : 1216-1223, 2019.
8) Colebatch AN, et al : Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis : a Cochrane systematic review. J Rheumatol Suppl 90 : 62-73, 2012.
9) Ramiro S, et al : Combination therapy for pain management in inflammatory arthritis : a Cochrane systematic review. J Rheumatol Suppl 90 : 47-55, 2012.
P.323 掲載の参考文献
1) Gotestam Skorpen C, et al : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75 : 795-810, 2016.
2) 「関節リウマチ (RA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班 : 厚生労働科学研究費補助金難治性疾患等政策研究事業 (難治性疾患政策研究事業) 全身性エリテマトーデス (SLE), 関節リウマチ (RA), 若年性特発性関節炎 (JIA) や炎症性腸疾患 (IBD) 罹患女性患者の妊娠, 出産を考えた治療指針, 2018.
3) Sammaritano LR, et al : 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 72 : 529-556, 2020.
4) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
5) Brouwer J, et al : Fertility in women with rheumatoid arthritis : influence of disease activity and medication. Ann Rheum Dis 74 : 1836-1841, 2015.
6) Reed SD, et al : Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J 10 : 361-366, 2006.
7) de Man YA, et al : Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight : results of a national prospective study. Arthritis Rheum 60 : 3196-3206, 2009.
8) Barrett JH, et al : Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 42 : 1219-1227, 1999.
9) Smeele HT, et al : Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients : the PreCARA study. Ann Rheum Dis 80 : 859-864, 2021.
10) Drossaers-Bakker KW, et al : Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis 61 : 405-408, 2002.
11) Weber-Schoendorfer C, et al : Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy : a prospective multicenter cohort study. Arthritis Rheumatol 66 : 1101-1110, 2014.
12) Weber-Schoendorfer C, et al : No evidence for an increased risk of adverse pregnancy outcome after paternal low-dose methotrexate : an observational cohort study. Rheumatology (Oxford) 53 : 757-763, 2014.
13) Eck LK, et al : Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy. Obstet Gynecol 129 : 707-714, 2017.
P.330 掲載の参考文献
1) 森雅亮 : 若年性特発性関節炎. 小児科臨床 69 : 661-667, 2016.
2) 武井修治, ほか : 小児慢性疾患におけるキャリーオーバー患者の現状と対策. 小児保健研究 66 : 623-631, 2007.
3) Fink CW : Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 22 : 1566-1569, 1995.
4) 厚生労働科学研究費補助金 (子ども家庭総合研究事業) 分担研究報告書研究課題 : 小慢データを利用した若年性特発性関節炎JIAの二次調査, 平成19年度総括・分担研究報告書, p102-113, 2008.
5) 若年性特発性関節炎初期診療の手引き 2015 (日本リウマチ学会小児リウマチ調査検討小委員会編), メディカルレビュー社, 2015.
6) 若年性特発性関節炎診療ハンドブック 2017 (日本リウマチ学会小児リウマチ調査検討小委員会編), メディカルレビュー社, 2017.
7) 成人診療科医のための小児リウマチ性疾患移行支援ガイド (厚生労働科学研究費補助金難治性疾患等政策研究事業小児期および成人移行期小児リウマチ患者の全国調査データの解析と両者の異同性に基づいた全国的「シームレス」診療ネットワーク構築による標準的治療の均てん化研究班編), 羊土社, 2020.
9) Mori M, et al : Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD) -refractory polyarticular course juvenile idiopathic arthritis : experience from Japanese clinical trials. Mod Rheumatol 21 : 572-578, 2011.
10) Imagawa T, et al : Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 31 : 1713-1721, 2012.
11) 若年性特発性関節炎 (JIA) における生物学的製剤使用の手引き [2020年版] (厚生労働科学研究費補助金難治性疾患等政策研究事業小児期および成人移行期小児リウマチ患者の全国調査データの解析と両者の異同性に基づいた全国的「シームレス」診療ネットワーク構築による標準的治療の均てん化研究班編), 羊土社, 2020.
P.334 掲載の参考文献
1) Kojima M, et al : Epidemiological characteristics of rheumatoid arthritis in Japan : Prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol 30 : 941-947, 2020.
2) Sugihara T : Treatment strategies for elderly-onset rheumatoid arthritis in the new era. Mod Rheumatol, 2021. (DOI : 10.1093/mr/roab087)
3) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
5) Sugihara T, et al : Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis : a 3-year prospective observational study. Rheumatology (Oxford) 60 : 4252-4261, 2021.
6) Radovits BJ, et al : Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis. Ann Rheum Dis 67 : 1127-1131, 2008.
7) Ito H, et al : Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis. Semin Arthritis Rheum 47 : 310-314, 2017.
8) Sugihara T, et al : Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis : a prospective cohort study (CRANE). Rheumatology (Oxford) 54 : 798-807, 2015.
9) Sugihara T, et al : Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. Mod Rheumatol, 2021. (DOI : 10.1080/14397595.2021.1912922)
10) Koike T, et al : Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21 : 343-351, 2011.
11) Koike T, et al : Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : interim analysis of 3881 patients. Ann Rheum Dis 70 : 2148-2151, 2011.
12) Harigai M, et al : Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 26 : 491-498, 2016.
13) Kasai S, et al : Higher risk of hospitalized infection, cardiovascular disease, and fracture in patients with rheumatoid arthritis determined using the Japanese health insurance database. Mod Rheumatol 29 : 788-794, 2019.
14) Kim HW, et al : Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol Int 35 : 727-734, 2015.
15) Kuroda T, et al : Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis. Intern Med 55 : 2777-2783, 2016.
P.339 掲載の参考文献
1) World Health Organization : Framework for Action on Interprofessional Education and Collaborative practice. [http://apps.who.int/iris/bitstream/handle/10665/70185/WHO_HRH_HPN_10.3_eng.pdf?sequence=1] (2022年3月閲覧)
2) Olenick M, et al : Interprofessional education : a concept analysis. Adv Med Educ Pract 1 : 75-84, 2010.
3) The Centre for the Advancement of Interprofessional Education (CAIPE). [https://www.caipe.org/] (2022年3月閲覧)
4) Barr H : Competent to collaborate : towards a competency-based model for interprofessional education. J Interprof Care 12 : 181-187. 1998.
5) 春田淳志 : 多職種連携コンピテンシーの国際比較. 保健医療福祉連携 9 : 106-115, 2016.
6) 日本クリニカルパス学会ホームページ. [http://www.jscp.gr.jp/about.html] (2022年3月閲覧)
P.346 掲載の参考文献
1) Smolen JS, et al : Rheumatoid arthritis. Lancet 388 : 2023-2038, 2016.
2) 松野博明 : 患者医療費負担を考慮した関節リウマチの治療-安価なconventional DMARDsによる治療. リウマチ科 58 : 600-606, 2017.
3) Matsuno H : Role of biosimilars in rheumatoid arthritis-Process from R & D to marketing and trends in the world. Clinical Case Reports and Reviews 7 : 1-5, 2021.
4) Matsuno H, Matsubara T : A randomized double-blind parallel-group phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. Mod Rheumatol 29 : 919-927, 2019.
5) Matsuno H, et al : Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate. Ann Rheum Dis 77 : 488-494, 2018.
6) Matsuno H, et al : A Comparison of the efficacy and safety of LBAL, a candidate adalimumab biosimilar, and adalimumab reference product in patients with active rheumatoid arthritis inadequately responding to methotrexate : a 52-week phase III randomised study. Clin Exp Rheumatol, 2021. (Online ahead of print)
7) Park MC, et al : Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101 : an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Res Ther 21 : 122, 2019.
8) Jorgensen KK, et al : Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH) : a 52-week, randomised, doubleblind, non-inferiority trial. Lancet 389 : 2304-2316, 2017.
9) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
10) 松野博明 : 関節リウマチ患者におけるエタネルセプトバイオシミラーから別のバイオシミラーへ切り替えた場合の有効性と安全性. 臨床リウマチ 32 : 245-250, 2020.
11) 松野博明 : 療養生活を支える社会福祉制度. よくわかる最新医学関節リウマチ (松野博明監), p151-157, 主婦の友社, 2020.
P.353 掲載の参考文献
1) 捧直太郎 : 令和2年度 (2020年度) 社会保障関係予算. 立法と調査 (420) : 110-127, 2020. [https://www.sangiin.go.jp/japanese/annai/chousa/rippou_chousa/backnumber/2020pdf/20200207110.pdf] (2022年3月閲覧)
2) 古元重和 : 日本における費用対効果評価の取り組み-費用対効果評価制度の概要-. 2019年2月25日国立保健医療科学院保険医療経済評価センター国際シンポジウム, 2019. [https://c2h.niph.go.jp/contents/event/MHLW_20190225.pdf] (2022年1月閲覧)
3) Tanno M, et al : Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan : a preliminary analysis. Mod Rheumatol 16 : 77-84, 2006.
5) Tanaka E, et al : Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Mod Rheumatol 27 : 227-236, 2017.
6) 費用の範囲や取り扱いについて (生産性損失等についての具体例). 福田参考人提出資料, 中医協費-2 25. 1. 23. [https://www.mhlw.go.jp/stf/shingi/2r9852000002tczq-att/2r9852000002td3l.pdf] (2022年1月閲覧)
7) Udeh BL : Economic Evaluation Studies. Chest 158 : S88-S96, 2020.
8) Gabriel S, et al : OMERACT 6 Economics Working Group report : a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 30 : 886-890, 2003.
9) Hoshi D, et al : Profiles of EQ-5D utility scores in the daily practice of Japanese patients with rheumatoid arthritis ; Analysis of the IORRA database. Mod Rheumatol 26 : 40-45, 2016.
10) 福田敬 : 医療技術の費用対効果の評価と活用. 中医協費-2 24. 5. 23. [https://www.mhlw.go.jp/stf/shingi/2r9852000002a7mj-att/2r9852000002anth.pdf] (2022年1月閲覧)
11) Shiroiwa T, et al : WTP for a QALY and health states : More money for severer health states? Cost Eff Resour Alloc 11 : 22, 2013.
12) Ryder HF, et al : Decision Analysis and Cost-effectiveness Analysis. Semin Spine Surg 21 : 216-222, 2009.
13) Sonnenberg FA, Beck JR : Markov models in medical decision making : a practical guide. Med Decis Making 13 : 322-338, 1993.
14) Joensuu JT, et al : The cost-effectiveness of biologics for the treatment of rheumatoid arthritis : a systematic review. PLoS One 10 : e0119683, 2015.
15) Wehler E, et al : A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. Pharmacoeconomics 38 : 39-56, 2020.
16) Tian F, et al : A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients. Medicine (Baltimore) 98 : e17750, 2019.
17) Drummond MF, et al : Methods for the Economic Evaluation of Health care Programmes, 4th ed, Oxford University Press, Oxford, 2015.
18) Husereau D, et al : Consolidated Health Economic Evaluation Reporting Standards (CHEERS) -explanation and elaboration : a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16 : 231-250, 2013.
19) 本多和典 : がん治療に伴う "経済毒性" の評価. 癌と化学療法 45 : 785-788, 2018.
P.358 掲載の参考文献
1) Williams MA, et al : Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. Health Technol Assess 19 : 1-222, 2015.
2) 林正春 : RA上肢病変に対するスプリント療法. 臨床リウマチ 24 : 279-289, 2012.
3) 日本リウマチ友の会 : 2020年リウマチ白書-リウマチ患者の実態 (資料編). 流 (363) : 32-33, 2021.
P.362 掲載の参考文献
1) Kameda H, et al : Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 29 : 31-40, 2019.
2) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
3) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), p20-30, 診断と治療社, 2021.
4) Kameda H, et al : Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis : a better response in male patients. Mod Rheumatol 14 : 442-446, 2004.
5) Takahashi C, et al : Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis : a 76-week prospective study. RMD Open 3 : e000363, 2017.
6) Cronstein BN, Aune TM : Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16 : 145-154, 2020.
7) Muto S, et al : Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis. Mod Rheumatol 31 : 1079-1086, 2021.
8) Yamakawa H, et al : Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). J Clin Med 10 : 3806, 2021.
9) Solomon DH, et al : Adverse Effects of Low-Dose Methotrexate : A Randomized Trial. Ann Intern Med 172 : 369-380, 2020.
10) Ibfelt EH, et al : Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis : a nationwide population-based study. Rheumatology (Oxford) 60 : 346-352, 2021.
11) Juge PA, et al : Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 57 : 2000337, 2021.
12) Kameda T, et al : Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66 : 1302-1309, 2014.
14) Honda S, et al : Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis : Results from a Japanese multi-institutional retrospective study. Mod Rheumatol 32 : 16-23, 2022.
15) Kuramoto N, et al : Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course : A retrospective, multicenter, case-control study. Mod Rheumatol 32 : 24-31, 2022.
P.367 掲載の参考文献
1) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2019 update. Ann Rheum Dis 79 : 685-699, 2020.
2) Nakajima A, et al : Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis 23 : 1676-1684, 2020.
3) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
7) Kawai S, et al : Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial. Mod Rheumatol 21 : 458-468, 2011.
8) Yamano Y, et al : Multidimensional improvement in connective tissue disease-associated interstitial lung disease : Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology 23 : 1041-1048, 2018.
10) Ishiguro N, et al : Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate : a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23 : 430-439, 2013.
11) Mimori T, et al : Safety and effectiveness of iguratimod in patients with rheumatoid arthritis : Final report of a 52-week, multicenter postmarketing surveillance study. Mod Rheumatol 29 : 314-323, 2019.
14) Sawada T, et al : Leflunomide-induced interstitial lung disease : prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford) 48 : 1069-1072, 2009.
15) Rau R, et al : Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis : 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 36 : 345-352, 1997.
P.375 掲載の参考文献
1) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
2) Westlake SL, et al : Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis : a systematic literature review. Rheumatology (Oxford) 50 : 518-531, 2011.
3) Takeuchi T, et al : Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis : the HOPEFUL 1 study. Ann Rheum Dis 73 : 536-543, 2014.
4) Atsumi T, et al : The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 75 : 75-83, 2016.
5) Tanaka Y, et al : Effectiveness and safety of initiating adalimumab plus ≧ 12 mg/week methotrexate with adjustable dosing in biologic-naive patients with early rheumatoid arthritis : HAWK study postmarketing surveillance in Japan. Mod Rheumatol 29 : 572-580, 2019.
6) Okuyama A, et al : Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70 : 299-304, 2011.
7) Curtis JR, et al : Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 56 : 1125-1133, 2007.
8) Dixon WG, et al : Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 : 2368-2376, 2006.
9) Komano Y, et al : Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors : a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38 : 1258-1264, 2011.
10) Nakajima A, et al : No increased mortality in patients with rheumatoid arthritis treated with biologics : results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23 : 945-952, 2013.
12) Menzies D, et al : Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 379 : 440-453, 2018.
13) Matsumoto T, Tanaka T : Continuation of anti-TNF therapy for rheumatoid arthritis in patients with active tuberculosis reactivated during anti-TNF medication is more beneficial than its cessation. J Infect Dis Ther 3 : 35-37, 2015.
14) Strangfeld A, et al : Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 76 : 504-510, 2017.
15) Xie F, et al : Tocilizumab and the risk of cardiovascular disease : direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 71 : 1004-1018, 2019.
16) Xie W, et al : A meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy. Rheumatology (Oxford) 59 : 930-939, 2020.
17) Takase K, et al : What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis 73 : 1695-1699, 2014.
18) Atzeni F, et al : Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 12 : 703-708, 2013.
19) Ishikawa Y, et al : Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab : A Retrospective Study of a Single Center Cohort. PLoS One 11 : e0162896, 2016.
20) Sakai R, et al : Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 64 : 1125-1134, 2012.
21) Sakai R, et al : No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis : epidemiological study using the Japanese health insurance database. Int J Rheum Dis 21 : 1670-1677, 2018.
P.380 掲載の参考文献
1) Klarenbeek NB, et al : The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70 : 1039-1046, 2011.
3) Smolen JS, et al : Treating rheumatoid arthritis to target : 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 : 3-15, 2016.
4) Ueda N, et al : The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis 19 : 1224-1231, 2013.
5) 関節リウマチ診療ガイドライン 2020 (日本リウマチ学会編), 診断と治療社, 2021.
7) 大坪秀雄, 松田剛正 : インフリキシマブ投与の実際. リウマチ科 36 : 562-569, 2006.
8) van der Bijl AE, et al : Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 56 : 2129-2134, 2007.
9) Maini R, et al : Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate : a randomised phase III trial. ATTRACT Study Group. Lancet 354 : 1932-1939, 1999.
10) Takeuchi T, et al : Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 70 : 1208-1215, 2011.
P.385 掲載の参考文献
1) 亀田秀人 : エタネルセプト. 日本臨牀 71 : 1214-1217, 2013.
2) Mitoma H, et al : Molecular mechanisms of action of anti-TNF-α agents-Comparison among therapeutic TNF-α antagonists. Cytokine 101 : 56-63, 2018.
4) Genovese MC, et al : Etanercept versus methotrexate in patients with early rheumatoid arthritis : two-year radiographic and clinical outcomes. Arthritis Rheum 46 : 1443-1450, 2002.
5) Moreland LW, et al : A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis : the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64 : 2824-2835, 2012.
6) Smolen JS, et al : Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomised controlled trial. Lancet 381 : 918-929, 2013.
7) Koike T, et al : Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21 : 343-351, 2011.